Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

CHE vs UNH vs CVS vs HUM vs MCK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
CHE
Chemed Corporation

Medical - Care Facilities

HealthcareNYSE • US
Market Cap$5.82B
5Y Perf.-11.0%
UNH
UnitedHealth Group Incorporated

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$335.60B
5Y Perf.+21.3%
CVS
CVS Health Corporation

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$111.40B
5Y Perf.+33.2%
HUM
Humana Inc.

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$29.67B
5Y Perf.-39.8%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$92.15B
5Y Perf.+374.1%

CHE vs UNH vs CVS vs HUM vs MCK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
CHE logoCHE
UNH logoUNH
CVS logoCVS
HUM logoHUM
MCK logoMCK
IndustryMedical - Care FacilitiesMedical - Healthcare PlansMedical - Healthcare PlansMedical - Healthcare PlansMedical - Distribution
Market Cap$5.82B$335.60B$111.40B$29.67B$92.15B
Revenue (TTM)$2.54B$449.71B$407.90B$137.20B$403.43B
Net Income (TTM)$260M$12.04B$2.93B$1.13B$4.76B
Gross Margin22.5%18.8%13.9%14.0%3.6%
Operating Margin12.9%4.2%1.5%1.0%1.5%
Forward P/E17.5x20.2x12.2x27.7x19.3x
Total Debt$155M$78.39B$93.59B$12.94B$7.39B
Cash & Equiv.$75M$24.36B$8.51B$4.20B$5.69B

CHE vs UNH vs CVS vs HUM vs MCKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

CHE
UNH
CVS
HUM
MCK
StockMay 20May 26Return
Chemed Corporation (CHE)10089.0-11.0%
UnitedHealth Group … (UNH)100121.3+21.3%
CVS Health Corporat… (CVS)100133.2+33.2%
Humana Inc. (HUM)10060.2-39.8%
McKesson Corporation (MCK)100474.1+374.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: CHE vs UNH vs CVS vs HUM vs MCK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CHE and CVS are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. CVS Health Corporation is the stronger pick specifically for valuation and capital efficiency and recent price momentum and sentiment. MCK and UNH also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
CHE
Chemed Corporation
The Defensive Pick

CHE has the current edge in this matchup, primarily because of its strength in sleep-well-at-night.

  • Lower volatility, beta 0.33, Low D/E 15.8%, current ratio 1.05x
  • 10.2% margin vs CVS's 0.7%
  • 15.9% ROA vs CVS's 1.1%, ROIC 23.7% vs 5.0%
Best for: sleep-well-at-night
UNH
UnitedHealth Group Incorporated
The Insurance Pick

UNH is the clearest fit if your priority is dividends.

  • 2.4% yield, 25-year raise streak, vs CVS's 3.1%
Best for: dividends
CVS
CVS Health Corporation
The Insurance Pick

CVS is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.

  • Dividend streak 0 yrs, beta 0.05, yield 3.1%
  • Beta 0.05, yield 3.1%, current ratio 0.84x
  • Lower P/E (12.2x vs 19.3x)
  • +34.7% vs CHE's -25.9%
Best for: income & stability and defensive
HUM
Humana Inc.
The Insurance Play

Among these 5 stocks, HUM doesn't own a clear edge in any measured category.

Best for: healthcare exposure
MCK
McKesson Corporation
The Growth Play

MCK ranks third and is worth considering specifically for growth exposure and long-term compounding.

  • Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
  • 348.1% 10Y total return vs CHE's 241.8%
  • 16.2% revenue growth vs CHE's 4.1%
  • Beta 0.04 vs UNH's 0.59
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthMCK logoMCK16.2% revenue growth vs CHE's 4.1%
ValueCVS logoCVSLower P/E (12.2x vs 19.3x)
Quality / MarginsCHE logoCHE10.2% margin vs CVS's 0.7%
Stability / SafetyMCK logoMCKBeta 0.04 vs UNH's 0.59
DividendsUNH logoUNH2.4% yield, 25-year raise streak, vs CVS's 3.1%
Momentum (1Y)CVS logoCVS+34.7% vs CHE's -25.9%
Efficiency (ROA)CHE logoCHE15.9% ROA vs CVS's 1.1%, ROIC 23.7% vs 5.0%

CHE vs UNH vs CVS vs HUM vs MCK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

CHEChemed Corporation
FY 2025
Segment Vitas
64.3%$1.7B
Segment Roto Rooter
35.7%$938M
UNHUnitedHealth Group Incorporated
FY 2025
Unitedhealthcare
94.4%$332.4B
Optumhealth
5.6%$19.8B
CVSCVS Health Corporation
FY 2025
Pharmacy Revenue
58.9%$229.0B
Premiums
34.6%$134.8B
Front Store Revenue
5.5%$21.5B
Product and Service, Other
1.0%$3.9B
HUMHumana Inc.
FY 2025
Insurance Segment
84.7%$124.6B
CenterWell Segment
15.3%$22.5B
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B

CHE vs UNH vs CVS vs HUM vs MCK — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCHELAGGINGHUM

Income & Cash Flow (Last 12 Months)

CHE leads this category, winning 4 of 6 comparable metrics.

UNH is the larger business by revenue, generating $449.7B annually — 177.0x CHE's $2.5B. CHE is the more profitable business, keeping 10.2% of every revenue dollar as net income compared to CVS's 0.7%. On growth, HUM holds the edge at +23.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricCHE logoCHEChemed CorporationUNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…HUM logoHUMHumana Inc.MCK logoMCKMcKesson Corporat…
RevenueTrailing 12 months$2.5B$449.7B$407.9B$137.2B$403.4B
EBITDAEarnings before interest/tax$377M$23.2B$10.5B$2.2B$6.8B
Net IncomeAfter-tax profit$260M$12.0B$2.9B$1.1B$4.8B
Free Cash FlowCash after capex$377M$19.7B$7.4B$1.3B$6.0B
Gross MarginGross profit ÷ Revenue+22.5%+18.8%+13.9%+14.0%+3.6%
Operating MarginEBIT ÷ Revenue+12.9%+4.2%+1.5%+1.0%+1.5%
Net MarginNet income ÷ Revenue+10.2%+2.7%+0.7%+0.8%+1.2%
FCF MarginFCF ÷ Revenue+14.8%+4.4%+1.8%+0.9%+1.5%
Rev. Growth (YoY)Latest quarter vs prior year+1.6%+2.0%+6.2%+23.5%+6.0%
EPS Growth (YoY)Latest quarter vs prior year-0.2%+0.7%+63.1%-4.6%+37.0%
CHE leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

CVS leads this category, winning 4 of 6 comparable metrics.

At 23.1x trailing earnings, CHE trades at a 63% valuation discount to CVS's 62.8x P/E. On an enterprise value basis, CVS's 13.1x EV/EBITDA is more attractive than MCK's 18.7x.

MetricCHE logoCHEChemed CorporationUNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…HUM logoHUMHumana Inc.MCK logoMCKMcKesson Corporat…
Market CapShares × price$5.8B$335.6B$111.4B$29.7B$92.1B
Enterprise ValueMkt cap + debt − cash$5.9B$389.6B$196.5B$38.4B$93.8B
Trailing P/EPrice ÷ TTM EPS23.12x27.95x62.81x25.12x29.25x
Forward P/EPrice ÷ next-FY EPS est.17.49x20.19x12.19x27.68x19.28x
PEG RatioP/E ÷ EPS growth rate0.75x
EV / EBITDAEnterprise value multiple14.65x16.70x13.11x16.87x18.74x
Price / SalesMarket cap ÷ Revenue2.30x0.75x0.28x0.23x0.26x
Price / BookPrice ÷ Book value/share6.26x3.31x1.47x1.68x
Price / FCFMarket cap ÷ FCF17.89x20.88x14.27x79.13x17.63x
CVS leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

CHE leads this category, winning 5 of 9 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $4 for CVS. CHE carries lower financial leverage with a 0.16x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), UNH scores 6/9 vs HUM's 5/9, reflecting solid financial health.

MetricCHE logoCHEChemed CorporationUNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…HUM logoHUMHumana Inc.MCK logoMCKMcKesson Corporat…
ROE (TTM)Return on equity+25.3%+11.5%+3.9%+6.2%+3.0%
ROA (TTM)Return on assets+15.9%+3.9%+1.1%+2.2%+5.7%
ROICReturn on invested capital+23.7%+9.2%+5.0%+4.1%+5.4%
ROCEReturn on capital employed+24.7%+9.7%+6.1%+4.0%+30.5%
Piotroski ScoreFundamental quality 0–956556
Debt / EquityFinancial leverage0.16x0.77x1.24x0.73x
Net DebtTotal debt minus cash$80M$54.0B$85.1B$8.7B$1.7B
Cash & Equiv.Liquid assets$75M$24.4B$8.5B$4.2B$5.7B
Total DebtShort + long-term debt$155M$78.4B$93.6B$12.9B$7.4B
Interest CoverageEBIT ÷ Interest expense107.24x4.71x2.11x3.08x33.79x
CHE leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

MCK leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $5,674 for HUM. Over the past 12 months, CVS leads with a +34.7% total return vs CHE's -25.9%. The 3-year compound annual growth rate (CAGR) favors MCK at 27.3% vs HUM's -21.7% — a key indicator of consistent wealth creation.

MetricCHE logoCHEChemed CorporationUNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…HUM logoHUMHumana Inc.MCK logoMCKMcKesson Corporat…
YTD ReturnYear-to-date+0.6%+10.6%+10.6%-6.2%-8.5%
1-Year ReturnPast 12 months-25.9%-3.2%+34.7%-1.0%+4.6%
3-Year ReturnCumulative with dividends-21.9%-19.9%+36.6%-51.9%+106.4%
5-Year ReturnCumulative with dividends-11.2%-2.6%+17.0%-43.3%+286.9%
10-Year ReturnCumulative with dividends+241.8%+220.6%+3.5%+59.8%+348.1%
CAGR (3Y)Annualised 3-year return-7.9%-7.1%+11.0%-21.7%+27.3%
MCK leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — CVS and MCK each lead in 1 of 2 comparable metrics.

MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than UNH's 0.59 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs CHE's 72.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCHE logoCHEChemed CorporationUNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…HUM logoHUMHumana Inc.MCK logoMCKMcKesson Corporat…
Beta (5Y)Sensitivity to S&P 5000.33x0.59x0.05x0.56x0.04x
52-Week HighHighest price in past year$583.96$395.52$88.63$315.35$999.00
52-Week LowLowest price in past year$365.20$234.60$58.35$163.11$637.00
% of 52W HighCurrent price vs 52-week peak+72.9%+93.5%+98.5%+78.4%+75.3%
RSI (14)Momentum oscillator 0–10064.775.969.376.616.2
Avg Volume (50D)Average daily shares traded274K7.9M7.4M1.6M757K
Evenly matched — CVS and MCK each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.

Analyst consensus: CHE as "Hold", UNH as "Buy", CVS as "Buy", HUM as "Hold", MCK as "Buy". Consensus price targets imply 33.8% upside for MCK (target: $1007) vs -0.5% for HUM (target: $246). For income investors, CVS offers the higher dividend yield at 3.06% vs MCK's 0.36%.

MetricCHE logoCHEChemed CorporationUNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…HUM logoHUMHumana Inc.MCK logoMCKMcKesson Corporat…
Analyst RatingConsensus buy/hold/sellHoldBuyBuyHoldBuy
Price TargetConsensus 12-month target$475.00$385.43$95.20$246.00$1006.50
# AnalystsCovering analysts952414431
Dividend YieldAnnual dividend ÷ price+0.5%+2.4%+3.1%+1.4%+0.4%
Dividend StreakConsecutive years of raises18250017
Dividend / ShareAnnual DPS$2.20$8.70$2.67$3.56$2.69
Buyback YieldShare repurchases ÷ mkt cap+7.4%+1.7%0.0%+0.5%+3.4%
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Key Takeaway

CHE leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CVS leads in 1 (Valuation Metrics). 2 tied.

Best OverallChemed Corporation (CHE)Leads 2 of 6 categories
Loading custom metrics...

CHE vs UNH vs CVS vs HUM vs MCK: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is CHE or UNH or CVS or HUM or MCK a better buy right now?

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus 4. 1% for Chemed Corporation (CHE). Chemed Corporation (CHE) offers the better valuation at 23. 1x trailing P/E (17. 5x forward), making it the more compelling value choice. Analysts rate UnitedHealth Group Incorporated (UNH) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — CHE or UNH or CVS or HUM or MCK?

On trailing P/E, Chemed Corporation (CHE) is the cheapest at 23.

1x versus CVS Health Corporation at 62. 8x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — CHE or UNH or CVS or HUM or MCK?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -43. 3% for Humana Inc. (HUM). Over 10 years, the gap is even starker: MCK returned +348. 1% versus CVS's +3. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — CHE or UNH or CVS or HUM or MCK?

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus UnitedHealth Group Incorporated's 0. 59β — meaning UNH is approximately 1261% more volatile than MCK relative to the S&P 500. On balance sheet safety, Chemed Corporation (CHE) carries a lower debt/equity ratio of 16% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — CHE or UNH or CVS or HUM or MCK?

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus 4. 1% for Chemed Corporation (CHE). On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 14. 9% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, HUM leads at 11. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — CHE or UNH or CVS or HUM or MCK?

Chemed Corporation (CHE) is the more profitable company, earning 10.

5% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 10. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CHE leads at 13. 4% versus 1. 1% for HUM. At the gross margin level — before operating expenses — CHE leads at 30. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is CHE or UNH or CVS or HUM or MCK more undervalued right now?

On forward earnings alone, CVS Health Corporation (CVS) trades at 12.

2x forward P/E versus 27. 7x for Humana Inc. — 15. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MCK: 33. 8% to $1006. 50.

08

Which pays a better dividend — CHE or UNH or CVS or HUM or MCK?

All stocks in this comparison pay dividends.

CVS Health Corporation (CVS) offers the highest yield at 3. 1%, versus 0. 4% for McKesson Corporation (MCK).

09

Is CHE or UNH or CVS or HUM or MCK better for a retirement portfolio?

For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), 3. 1% yield). Both have compounded well over 10 years (CVS: +3. 5%, HUM: +59. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between CHE and UNH and CVS and HUM and MCK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CHE is a small-cap quality compounder stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap income-oriented stock; HUM is a mid-cap quality compounder stock; MCK is a mid-cap high-growth stock. CHE, UNH, CVS, HUM pay a dividend while MCK does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

CHE

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 6%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

UNH

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Dividend Yield > 0.9%
Run This Screen
Stocks Like

CVS

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 1.2%
Run This Screen
Stocks Like

HUM

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform CHE and UNH and CVS and HUM and MCK on the metrics below

Revenue Growth>
%
(CHE: 1.6% · UNH: 2.0%)
Net Margin>
%
(CHE: 10.2% · UNH: 2.7%)
P/E Ratio<
x
(CHE: 23.1x · UNH: 27.9x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.